Skip to content
lifestyle.wordsjournal.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nasus Pharma, Ltd.
Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
November 10, 2026
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
September 29, 2026
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
September 14, 2026
Nasus Pharma to Present at H.C. Wainwright Global Investment Conference
September 8, 2026
Nasus Pharma Announces Transition of Chief Financial Officer
August 19, 2026
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
August 17, 2026
Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth
July 28, 2026
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
February 11, 2026